New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists
Authors
Keywords
Thrombin, International Normalize Ratio, Dabigatran, Rivaroxaban, Apixaban
Journal
CLINICAL PHARMACOKINETICS
Volume 52, Issue 2, Pages 69-82
Publisher
Springer Nature
Online
2013-01-04
DOI
10.1007/s40262-012-0030-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Coadministration of Dabigatran Etexilate and Atorvastatin
- (2013) Joachim Stangier et al. American Journal of Cardiovascular Drugs
- Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification
- (2012) Andreas Clemens et al. CURRENT MEDICAL RESEARCH AND OPINION
- Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation
- (2012) H. Kamel et al. NEUROLOGY
- Dabigatran Etexilate
- (2012) Kate McKeage PHARMACOECONOMICS
- Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
- (2012) Soyon Lee et al. PLoS One
- The Role of Apixaban for Venous and Arterial Thromboembolic Disease
- (2011) Rathasen Prom et al. ANNALS OF PHARMACOTHERAPY
- Guidelines on oral anticoagulation with warfarin - fourth edition
- (2011) David Keeling et al. BRITISH JOURNAL OF HAEMATOLOGY
- Dabigatran Etexilate
- (2011) Graeme J. Hankey et al. CIRCULATION
- Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate
- (2011) Elise S. Eerenberg et al. CIRCULATION
- Rivaroxaban
- (2011) Wolfgang Mueck et al. CLINICAL PHARMACOKINETICS
- Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor
- (2011) Kan He et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
- (2011) M. J. Gnoth et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
- (2011) Pancras C. Wong et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism
- (2010) Bengt I. Eriksson et al. Annual Review of Medicine
- Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin
- (2010) Wolfgang G. Eisert et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
- (2010) Dagmar Kubitza et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- New Anticoagulants
- (2010) John W. Eikelboom et al. CIRCULATION
- Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate
- (2010) Joachim Stangier et al. CLINICAL PHARMACOKINETICS
- Dabigatran Acylglucuronide, the Major Human Metabolite of Dabigatran: In Vitro Formation, Stability, and Pharmacological Activity
- (2010) T. Ebner et al. DRUG METABOLISM AND DISPOSITION
- New oral antithrombotics: a need for laboratory monitoring. Against
- (2010) H. BOUNAMEAUX et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Newly Identified Events in the RE-LY Trial
- (2010) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay
- (2010) Zhaoqing Wang et al. THROMBOSIS AND HAEMOSTASIS
- Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: Comparison with direct inhibitors of factor VIIa, XIa and thrombin
- (2010) Xiaosui Jiang et al. THROMBOSIS AND HAEMOSTASIS
- Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
- (2010) Joachim Stangier et al. THROMBOSIS AND HAEMOSTASIS
- In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves
- (2010) Lars Maegdefessel et al. THROMBOSIS RESEARCH
- Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery
- (2009) Wolfgang Mueck et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects
- (2009) Joachim Stangier et al. CLINICAL PHARMACOKINETICS
- In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans
- (2009) D. Lang et al. DRUG METABOLISM AND DISPOSITION
- In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies
- (2009) L. Wang et al. DRUG METABOLISM AND DISPOSITION
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- New oral anticoagulants in development
- (2009) J. I. Weitz THROMBOSIS AND HAEMOSTASIS
- New Anticoagulants for Treatment of Venous Thromboembolism
- (2008) Peter L. Gross et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Pharmacogenetics of Oral Anticoagulants
- (2008) Simone Stehle et al. CLINICAL PHARMACOKINETICS
- Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
- (2008) Bengt I Eriksson et al. CLINICAL PHARMACOKINETICS
- Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
- (2008) Dagmar Kubitza et al. CURRENT MEDICAL RESEARCH AND OPINION
- Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
- (2008) N. Raghavan et al. DRUG METABOLISM AND DISPOSITION
- Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment
- (2008) Joachim Stangier et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits
- (2008) P. C. WONG et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Apixaban, an oral, direct and highly selective factor Xa inhibitor:in vitro, antithrombotic and antihemostatic studies
- (2008) P. C. WONG et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started